The comprehensive process of monoclonal antibody development, production,
characterization, and specification in the European context are engineered to precisely target
various threats and have revolutionized medical approaches against diseases like cancer and
infections. In Europe, European Medicines Agency (EMA) plays a prominent role in ensuring
quality by establishing stringent guidelines across four distinct stages: development,
production, characterization, and specification. The Development phase focuses on aligning
antibody structure with its intended mechanism, biological activity, and stability. In
Production, a meticulous manufacturing process description and validation are central aspects.
Characterization involves a comprehensive evaluation of attributes like physicochemistry,
immunochemical properties, biological activity, purity, impurities, and quantity. In the
Specification stage, maintaining product consistency and compliance is paramount. Finally harmonized approach across the Different stages ensures that monoclonal antibodies and
related products adhere to the highest quality standards. EMA's stringent guidelines provide a
robust framework for developing targeted, effective, and safer therapeutic solutions, thereby
transforming medical practices and patient care. The revolutionary potential of monoclonal
antibodies helps to reshape healthcare needs.
Keywords: EMA, Monoclonal Antibody, Safety, Specification, Characterization, B-
lymphocytes, TSE/BSE
Publication date: 01/09/2025
https://ijbpas.com/pdf/2025/September/MS_IJBPAS_2025_9330.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.9.9330
